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Abstract
Pregnancy reduces maternal risk of breast cancer in the long-term, but the biological determinants
of the protection are unknown. Animal experiments suggest that estrogens and progesterone could
be involved, but direct human evidence is scant. A case-control study (536 cases, 1,049 controls)
was nested within the Finnish Maternity Cohort. Eligible were primiparous women, who delivered
at term a singleton offspring before age 40. For each case, two individually matched controls by
age (±6 months) and date of sampling (±3 months) were selected. Estradiol, estrone, and
progesterone in first-trimester serum were measured by High Performance Liquid
Chromatography Tandem Mass Spectrometry and sex-hormone binding globulin (SHBG) by
immunoassay. Odds ratios (OR) and 95% confidence intervals (CI) were estimated through
conditional logistic regression. In the whole study population, there was no association of breast
cancer with any of the studied hormones. In analyses stratified by age at diagnosis, however,
estradiol concentrations were positively associated with risk of breast cancer before age 40 (upper
quartile OR, 1.81; CI, 1.08-3.06), but inversely associated with risk in women who were
diagnosed ≥age 40 (upper quartile OR, 0.64; CI, 0.40-1.04), pinteraction 0.004. Risk estimates for
estrone mirrored those for estradiol, but were less pronounced. Progesterone was not associated
with risk of subsequent breast cancer. Our results provide initial evidence that concentrations of
estrogens during the early parts of a primiparous pregnancy are associated with maternal risk of
breast cancer and suggest that the effect may differ for tumors diagnosed before and after age 40.
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INTRODUCTION
Maternal elevations in sex-steroid hormones during gestation are likely to be involved in the
molecular changes that underlie the effect of pregnancy on risk of breast cancer.1, 2 In
several rodent species, treatment of young virgin animals prior to carcinogen exposure with
high concentrations of estradiol and progesterone of duration equivalent to that of a normal
pregnancy successfully reproduces the protection against mammary carcinogenesis that a
natural pregnancy confers.2, 3 Treatment with these hormones sharply curtails overall
incidence, the number of tumors per animal, and prolongs latency.2, 3 However, in humans,
the association of pregnancy, and likely of sex-steroids, with maternal risk is complex: early
age at first completed pregnancy is crucial for the establishment of protection4, childbirth is
followed by a transient increase in risk5, 6 and the protective effect becomes apparent only
after age 40-457-10. Recent epidemiological evidence strongly suggests that the well-
established inverse associations of parity and early age at first birth with breast cancer are
driven by associations with estrogen receptor (ER)-positive breast cancer (which accounts
for about 80% of all diagnosed tumors), while they are not associated with risk of hormone-
receptor negative disease 11, 12 and may be related to increased risk of triple negative
tumors 11. So far, direct human data on the association of sex-steroids during pregnancy
with breast cancer are limited to a single nested case-control study (194 cases) in which third
trimester progesterone tended to be inversely associated with risk, but the associations with
estrogens were less clear.13
The present study was designed to address the hypothesis that maternal breast cancer risk is
reduced in women who experience comparatively elevated concentrations of estradiol,
estrone, progesterone and sex hormone binding globulin (SHBG, the major protein carrier of
estradiol in the circulation) during their first full-term primiparous pregnancy (FTP) as
suggested by experimental studies3. We hypothesized that the protective association would
be stronger the younger the age of the mother at pregnancy in line with the established direct
association of breast cancer with age at first completed pregnancy. Additionally, we wanted
to explore possible effect modification by age at breast cancer diagnosis (as pregnancy
protects against breast cancer only after age 40, when the proportion of hormone receptor-
positive disease increases and that of hormone receptor-negative disease decreases) and time
to cancer diagnosis.
MATERIALS AND METHODS
Study population
The Finnish Maternity Cohort (FMC) stores at −25°C more than 1.3 million serum samples
collected during the latter part of the first, or the early weeks of the second trimester.14 The
biobank contains serum samples from more than 98% of all pregnancies in the country since
1983.
Selection of cases and controls
A case-control study was nested within the FMC. Eligible were FMC members with samples
donated during 6 to 14 gestational week of a primiparous, singleton, full-term pregnancy
(defined as pregnancy lasting ≥37 and <44 weeks), who were less than age 40 at blood
collection with no history of in-situ breast or any invasive cancer (except non-melanoma
skin cancer). To maximize study efficiency to explore effect modification by age at first
pregnancy within a limited budget, all cases in the category of age at first FTP with smallest
number of cases (< 25 years, n=263) were included and the same number of cases (263)
from each of the other 3 age at first FTP categories (25-29, 30-34, 35-39) were selected at
random (total 1,052 cases).
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Incident invasive breast cancers diagnosed >6 months after blood donation among FMC
members were identified through a linkage of a restricted FMC file (containing limited
information on parity and gestational age) with the Finnish Cancer Registry (Figure 1). The
smallest number of cases were observed in the youngest maternal age group (n=263) and an
equal number of cases in each of the 3 older age groups were selected at random. Up to 12
potentially eligible controls per each case matched on age at sampling (±6 months), date of
sampling (±3 months) and who were alive at the time of the diagnosis of the index case were
identified.
A linkage with the Finnish Population Registry led to the exclusion of 254 cases who did not
meet the primiparous, singleton, or full-term pregnancy requirement. Cases with
unverifiable information about gestational day at blood collection (necessary to account for
hormone variations during pregnancy, n=185) or with no serum samples (n=73) were also
excluded. Among the eligible, individually matched controls per each case, two were
selected at random. For 23 cases only one eligible control was available and 4 cases with no
eligible controls were further excluded. In total, 536 cases and 1,049 controls were retained
for the study. Information on first FTP was obtained through a linkage with the Finnish
Birth Registry and on malignant cancers diagnosed among first degree relatives of the study
subjects from linkages with the Population and Cancer Registries.
Laboratory analyses
Hormonal analyses were performed at the University Hospital in Umeå, Sweden by
technicians unaware of the case, control, or quality control status of the specimens. Samples
of individually matched cases and controls were always included in the same laboratory run.
A pool of serum from the cohort was created at the beginning of the study and 2 aliquots,
undistinguishable from the test samples, were inserted in each laboratory run. Sex-steroids
were quantified by High Performance Liquid Chromatography Tandem Mass Spectrometry
on an Applied Biosystems API4000 triple stage quadrupole mass spectrometer. Laboratory
quality controls most closely corresponding to the levels observed in the population: 2.5 ng/
mL for estradiol and estrone and 50 ng/mL for progesterone, showed coefficients of
variation (CV) of 10.3% or lower. Intra- and inter-run CV based on the blinded pool of
quality controls were 9.1% or lower. Sex hormone binding globulin (SHBG) was quantified
with a solid-phase competitive chemiluminescence assays on Immulite 2000 Siemens
analyzer. The intra- and inter-run CV estimated from analyses of laboratory quality controls
of 84 nmol/L were ≤5.5%, whereas those based on the quality controls from the blind pool
were ≤7.6%. One progesterone measurement exceeding 3 times the interquartile range was
set to missing.
Statistical analysis
Prior to analysis, original hormone values were log2-transformed to normalize their
distributions. As expected, hormone concentrations increased linearly with gestational age
(Figure 2) and all statistical analyses were adjusted for gestational age.
The conditional logistic regression model (appropriate for the individually matched design)
was used to calculate odds ratios (OR) and corresponding 95% confidence intervals (CI).
Subjects were classified in quartiles using the frequency distribution of all controls. The
associations of breast cancer with hormone concentrations were investigated in all women
and in subgroups by the median of ages at first FTP (30 years) and diagnosis (40 years), and
lag-time to diagnosis (10 years). The median cut-off points were chosen as they provide the
greatest statistical power for the sub-group analyses. Coincidentally, they correspond to
biologically relevant categories (epidemiological studies have shown that the protective
effect of pregnancy is confined to women who give birth before age 307, in comparison with
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nulliparous women parous women are at decreased risk of breast cancer after age 40-458,
and the transient increase in breast cancer risk after a pregnancy is evident for about 10
years6). Likelihood ratio tests were used to assess trends in ORs with assigned quantitative
scores 1, 2, 3, and 4 for the categories.
Further analyses in finer sub-categories of age at first FTP (<25, 25-29, 30–34 and 35–39),
age at diagnosis (<35, 35-39, 40-44 and ≥45) and lag-time (<5, 5-9, 10–14 and ≥15 years)
and combinations of these were conducted. For analyses based on small number of cases,
risk estimates were calculated on the continuous scale of the log2-hormone variables, a unit
increase of which corresponds to a doubling of concentrations. Associations were also
explored by histological subtypes of the tumors, parity to index date (cancer diagnosis) and
according to categories of time between the first and subsequent pregnancies. Tests of
homogeneity between the odds ratios in different subgroups were based on chi-square
statistics.15 Adjustment for potential confounders (prior gravidity, parity by index date,
characteristics of the first FTP and family history of breast cancer) mostly had only
negligible effect on risk estimates (occasional estimates changed up to 4.8%) and were not
retained in the final models. Estradiol models were additionally adjusted for progesterone
and SHBG. Risk estimates for combined exposure to estradiol and progesterone (above or
below the median) were also calculated. All analyses were repeated with hormone
concentrations for each study subject computed as the difference (residual) between the
assay value and the estimated mean value determined for the day of gestation when the
sample was drawn using local linear regression.16 As results were very similar to those
obtained from models including log2-transformed hormone values adjusted for gestational
age, only the latter are presented. All tests of statistical significance were two-sided and
considered significant if the p-values were <0.05.
The study was approved by the ethical committee of the National Institute for Health and
Welfare, Finland.
RESULTS
Cases and controls were comparable in all characteristics listed in Table 1, except for family
history of breast cancer, which was observed in twice as many cases than controls. For the
cases, median age at diagnosis was 40.0 years. Only 26 cases were diagnosed after age 50.
The proportions of women with lobular and localized disease were significantly higher in
women diagnosed after age 40 than in women diagnosed before that age (19% versus 9%
and 52% versus 41%, respectively).
Among study participants overall none of the hormones was related to risk of breast cancer.
However, analyses by median ages at diagnosis and first FTP revealed a heterogeneity of the
associations by age at diagnosis for estradiol, estrone and SHBG and by age at first FTP for
estradiol (Table 2).
Estrogens were associated with significantly increased risk of breast cancer before age 40
and decreased risk (significant only for doubling of concentrations) for cancers diagnosed
≥40 years (Table 2). Risk estimates for estradiol were very similar in the bottom two (<35
and 35-39) and upper two (40-44 and ≥45) age at diagnosis categories (OR 1.70 (0.78-3.71),
1.72 (0.85-3.50), 0.64 (0.35-1.20) and 0.59 (0.27-1.29), respectively).
Estradiol concentrations tended to be inversely associated with breast cancer risk in women
who had their first FTP at age 30 or older, while the opposite was observed for those with
first FTP before age 30 (both associations of borderline significance). Analyses in quartiles
of maternal age were less clear (e.g. for estradiol top quartile ORs were 1.29 (0.61-2.70),
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1.69 (0.89-3.24), 0.51 (0.25-1.03) and 0.80 (0.38-1.69) for women age <25, 25-29, 30-34
and 35-39 at first FTP).
Combined analyses by medians of ages at first FTP and diagnosis are presented in Table 3.
There was no indication for heterogeneity of the associations of breast cancer with any of
the studied hormones by maternal age at first FTP in women diagnosed either before or after
age 40. The heterogeneity by age at diagnosis, however, remained significant for doubling
of estradiol in women above age 30 at first FTP and for doubling of estrone for women
below age 30 (results for estradiol in this sub-group were in the same direction, but not
significant (p=0.07)), suggesting that the observed differences by age at first pregnancy
could have been influenced by the heterogeneity by age at diagnosis.
Analyses by the median lag-time to diagnosis did not indicate heterogeneity of the effect for
any of the hormones. However, an increased risk with doubling of estradiol concentrations
was observed in women diagnosed within 5 years of the first FTP both below and above age
30 and among women diagnosed before age 40 (Table 4). Combined analyses by age at first
FTP, age at diagnosis and lag-time were not informative because of the interrelation
between these variables resulting in limited number of subjects in some of the subgroups.
Progesterone concentrations were not related to risk. In analyses in quartiles, SHBG
concentrations were significantly associated with risk only in women with diagnosis before
age 40, but after adjustment for estradiol the association was no longer significant.
Adjustment of estradiol models for progesterone did not change the direction or the
significance of the observed associations. Analyses by combined estradiol and progesterone
exposure below or above the median yielded similar results to those overall. Adjustment for
SHBG attenuated some of the associations and the results across quartiles of estradiol in
women diagnosed below age 40 were no longer significant (1.60 (0.89-2.88), p=0.14), but
the association remained different from that in women diagnosed at or after age 40
(pint<0.05).
Adjustment for potential confounders had only negligible effect on risk estimates. Results
for ductal carcinoma were similar or stronger to those reported overall. Analyses excluding
women with family history of breast cancer or women diagnosed after age 50 yielded almost
identical results. In multiparous women at diagnosis, doubling of estradiol and estrone
concentrations was associated with significantly increased risk in those diagnosed before age
40, with risk estimates very similar in women who had a subsequent pregnancy ≤ 2 years or
> 2 years of first FTP. Results in uniparous and biparous women were largely similar to
those overall, but did not reach statistical significance with the exception for estradiol in
biparous women with lag-time < 10 years (OR 1.65 (1.01-2.68) and for estrone in women
diagnosed above age 40 (OR 0.58 (0.38-0.88)) and lag-time ≥10 years (OR 0.72
(0.52-0.98)).
DISCUSSION
This study is the first to offer direct epidemiological evidence that estrogens during the early
part of a first FTP are involved of the complex relationship between pregnancy and breast
cancer. Our observations suggest that the effect of hormones differ by age at breast cancer
diagnosis. The strongest associations were observed for estradiol, the most potent natural
estrogen. In comparison with women with first trimester estradiol concentrations in the
lowest quartile, those in the top quartile had 80% increase in risk of breast cancer occurring
before age 40, while the same concentrations of the hormone decreased risk of cancer after
that age by 36%. Associations with estrone, highly correlated with estradiol, followed
similar patterns, whereas there was no association with progesterone.
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Our results on first trimester hormones differ from those in the only other reported study on
pregnancy sex steroids and risk of maternal breast cancer, where third trimester samples
were analyzed.13 Estrogens may be most strongly related to risk during the first trimester,
when the proliferation of breast epithelium is at its peak17-19, which can account for our
findings and explain the lack of clear association in the study by Peck et al13. In contrast, as
observed by Peck et al.13, progesterone concentrations could be of relevance in the latter
parts of pregnancy, after the initial proliferation of breast ductal epithelium and sufficient
expression of the PR-receptor induced by estrogens had set the stage necessary for
progesterone to stimulate a complete lobulo-alveolar differentiation of the breast.17-19
Breast cancer is a heterogeneous disease. Epidemiological studies have shown that the effect
of risk factors differs both by menopausal status and by tumor expression of estrogen and
progesterone receptors (PR).10-12, 20, 21 Our findings concern mostly premenopausal breast
cancer as 95% of the cases were diagnosed before age 50. Nevertheless, the proportion of
hormone receptor-positive tumors is likely to differ by age at diagnosis, as it is about 11%
higher in women diagnosed at age 40 to 49, as compared to those diagnosed at age 30-39,
and the difference is larger across wider age-ranges.22 Additionally, the proportion of triple
negative tumors decreases with age.23 Differences by tumor receptor expression are possibly
of greatest relevance to our results, as pregnancy confers protection against hormone
receptor-positive disease, is not associated with hormone receptor-negative breast cancer,
and may increase risk of triple negative tumors.11, 12, 23
The decrease in maternal breast cancer after age 40 associated with elevated estrogens is in
line with the well-established long-term protection conferred by pregnancy, and specifically
against ER-positive disease, which increases in incidence with age.22, 24 Experimental data
also support such interpretation, as treatment with estradiol and progesterone prior to
carcinogen exposure has been shown to block the proliferation of ER-positive cells and to
reduce the incidence of tumors which are largely (80%) hormone-responsive.2, 3, 25 The
mechanisms underlying the protective effect have not yet been identified, but terminal
differentiation of epithelial breast cells to a state less susceptible to transformation, reduced
number of mammary stem cells, and changes in estrogen responsiveness of the parous
glands have been proposed.1
We speculate that the increased risk of breast cancer before age 40 associated with estrogens
in our data could be driven, at least in part, by a direct association of estrogens with ER-
negative breast cancer (particularly triple negative tumors). In comparison with women
diagnosed after 40, those diagnosed before that age have higher proportion of receptor-
negative tumors and lower proportion of receptor-positive tumors 22. Animal models of
parturition-induced receptor-negative breast cancer have demonstrated that despite the lack
of estrogen receptors, these tumors require estrogen for their formation and progression.26
High background estrogen concentrations appear important in the development of receptor-
negative tumors also in humans, as their incidence is higher before menopause and then
plateaus and decreases with the transition to menopause and low estrogen environment.27
The association of circulating estrogens with ER-negative breast cancer remains to be
characterized. Prospective studies in postmenopausal women (all including less than 42 ER-
negative cases) have shown mixed results. 28-31 Similar risk estimates for the association of
estradiol with both ER-positive and ER-negative disease were found in two studies 28,29 and
in one a direct strong association with ER-positive, but not with ER negative disease was
observed 30.
Another possible interpretation is that some women might be especially vulnerable to the
massive push to cell proliferation that estrogens induce during pregnancy. Several large
record-linkage studies have described a transient increase in maternal breast cancer that
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peaks about 5 years after delivery.5, 6 In line with these findings, the increase in breast
cancer risk before age 40 associated with doubling of estradiol concentrations was stronger
in women diagnosed within 5 years of their first pregnancy. One group of susceptible
women could be those carriers of deleterious BRCA1 mutations, who have been shown to
experience disturbed development and differentiation of the breast epithelium during
pregnancy32, 33, to develop the disease at young age and possibly be at particularly elevated
risk following pregnancy34. However, study results were unaffected when women with
family history of breast cancer were excluded.
The major strengths of this large study in young women are its prospective design and that it
was conducted within a well-defined cohort of primiparous women who delivered a child at
term. The first completed pregnancy is associated with profound changes both in the
maternal breasts and in hormone concentrations, which tend to be lower during subsequent
pregnancies.35, 36 The matching on age of first FTP and the additional information on the
first FTP, women’s overall parity and cancer occurrence in first degree relatives allowed us
to control for several sources of potential confounding.
The major study limitation is the lack of information on receptor status of the tumors
necessary to fully characterize and understand the observed associations with risk.
Unfortunately this information is not collected centrally in Finland. Additionally, given the
correlation between maternal age at first FTP pregnancy, age at cancer diagnosis and lag-
time to diagnosis, a substantially larger study would be necessary to investigate in sufficient
detail and with adequate statistical power the individual contribution of each of these factors
as potential effect modifiers of the association of breast cancer with hormone concentrations
during pregnancy. Study samples had been stored at relatively high temperature (−25°C),
but cases and controls were tightly matched on date of sampling. Reassurance that our
results were not influenced in a major way by possible analyte degradation is that hormone
levels were uncorrelated with time in storage (as also reported previously37), and their
concentrations varied with gestational age as expected. A large number of potentially
eligible cases were excluded from the study. However, as the exclusions were made either at
random (to reduce the number of cases because of financial constraints) or affected in non-
differential way both the case and control subjects (e.g. exclusion of all women with blood
donation prior to 1986 to be able to control for hormone variation with gestational day), it is
unlikely that they have affected our results in a systematic way. Finally, we cannot exclude
the possibility of chance findings and confirmation of our results in other and larger studies
is necessary.
In conclusion, our results support the hypothesis that comparatively elevated estrogen
concentrations during the first trimester of a first FTP could be involved in protection that a
pregnancy affords the mother after age 40. Comparative elevations in the same hormones
could be associated with an increase in risk of breast cancer before age 40. Confirmation of
our findings is of interest, given the growing interest in the possibility of utilizing pregnancy
hormones as chemopreventive agents in young women.38
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Figure 1.
Selection of study cases among women identified as potentially eligible after initial linkage
of a restricted FMC file with data from the Finnish Cancer Registry. (Because of logistic
difficulties, control eligibility was verified only for those matching a case included in the
study.)
Footnote: Gestational age at blood donation was available only for women recruited after
1986 and all subjects recruited prior to that year (of which 171 were cases) were excluded
from the study.
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Figure 2.
Distribution of log2 hormone concentrations (case and control subjects) by gestational day.
The solid line shows the progression of hormone concentrations during pregnancy,
estimated by linear regression.
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Table 1
Selected characteristics of study subjects and first FTP, median (range) or number (percent)
Characteristic Cases (536) Controls (1,049) P Value**
Age at first FTP, years 29·9 (18·4-40·0) 29·9 (18·0-40·0)
Age at first FTP
   < 25 123 (23) 240 (23)
   25 - 29 147 (27) 291 (28)
   30 - 34 137 (26) 272 (26)
   35 - 39 129 (24) 246 (23)
Gestational day at blood donation 67 (39-95) 68 (40-95) 0·32
Primigravida 415 (79) 818 (80) 0·63
Parity by index date (cancer diagnosis) 0·41
   1 197 (37) 387 (37)
   2 244 (46) 451 (43)
   > 2 95 (18) 211 (20)
Time between first FTP and subsequent 0.85
pregnancy in multiparous women* 2.36 (0.91-13.8) 2.38 (0.87-12.8)
Child gender 0.85
   Boy 274 (51) 531 (51)
   Girl 262 (49) 518 (49)
Child weight, g † 3,490 (2,220-5,185) 3,505 (1,630-5,530) 0·86
Child length, cm † 50·0 (44·0-56·0) 50·0 (41·0-58·0) 0·58
Use of assisted reproduction techniques† 0·27
   No 523 (99) 1,017 (98)
   Yes 7 (1) 22 (2)
Diabetes treated with insulin † 0·73
   No 529 (100) 1,036 (100)
   Yes 1 3
Hypertension during pregnancy † 0·24
   No 511 (96) 1,012 (97)
   Yes 19 (4) 27 (3)
Hospitalization during pregnancy † 0·88
   No 475 (90) 933 (90)
   Yes 55 (10) 106 (10)
Smoking † 0·17
   No 431 (83) 873 (86)
   yes 86 (17) 143 (14)
Socio-economic status 0·36
   low 191 (36) 388 (37)
   high 80 (15) 126 (12)
   other 25 (5) 50 (5)
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Characteristic Cases (536) Controls (1,049) P Value**
   missing 240 (45) 485 (46)
≥1 1st degree relative with breast cancer 60 (11) 48 (5) <0·0001
Strong family history of breast cancer ‡ 22 (4) 17 (2) 0·003
Age at cancer diagnosis, years 40·0 (23·6-56·3) -
Lag-time to diagnosis, years 10·1 (1·1-19·0) -
Tumor histology
   Ductal 414 (77) -
   Lobular 73 (14) -
   Others / unknown 49 (9) -
Tumor spread
   Local 227 (42) -
   Regional or distant 262 (49) -
   Others / unknown 47 (9) -
Estradiol §, ng/mL 1·70 (1·64-1·76) 1·70 (1·66-1·74) 0·96
Estrone §, ng/mL 0·70 (0·70-0·73) 0·71 (0·68-0·73) 0·84
Progesterone §, ng/mL 25·0 (24·4-25·7) 25·1 (24·6-25·6) 0·87
SHBG §, nmol/L 168 (163-173) 168 (164-171) 0·92
*
by date of cancer diagnosis
†
Information from the Finnish Birth Registry is missing for 6 cases and 10 controls
‡
First degree relatives with breast cancer diagnosed < age 50 or families with ≥ 2 breast cancer cases
§
Geometric mean (10th - 90th percentile)
**
p-values calculated by conditional logistic regression
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